Danish firm, Aussie instiute to co-develop pathological drugs

Posted in News, World

Updated on 8 November 2013

Danish firm, Mirrx Therapeutics and Australia’s Centenary Institute of Cancer Medicine and Cell Biology has formed a collaboration and commercialisation agreement, which formalises a long standing collaboration to discover and develop therapeutic oligonucleotide drug candidates targeting vascular endothelial cadherin (VE-cadherin).

Pharmacological modulation of VE-cadherin expression has the potential to treat a broad range of diseases for which regulation of vascular permeability and angiogenesis are important; including ischemic conditions, inflammation, oedema and solid tumours. The Agreement includes cross-licensing of patents, collaborative research and joint commercialisation activities.

• Continue Reading

Eisai expands its anti-obesity drug market

Posted in News, World

Updated on 8 November 2013

Expanded agreement now includes most countries and territories including European Union, Japan and China

Global pharmaceutical firm, Eisai has expanded the marketing and supply agreement between its U.S. subsidiary Eisai Inc. and U.S-based Arena Pharmaceuticals’s Swiss subsidiary, Arena Pharmaceuticals, for anti-obesity agent lorcaserin hydrochloride (lorcaserin) (U.S. brand name: BELVIQ).

• Continue Reading